Reinventing Launch: The Gold Standard Of Drug Commercialization

The Only Proven Complete Commercialization Expert in the Industry

On average, manufacturers spend >$125MM over three years leading up to launch, yet 66% of drugs don’t meet launch expectations. An unpredictable landscape, coupled with inevitable industry pressures, is forcing manufacturers to seek a more complete commercialization approach with less risk and more value.

For the past three years, EVERSANA, a leading provider of commercial services to the life sciences industry, has been implementing a complete, full-scale, customized model for product commercialization into client strategy. Our end-to-end commercialization engine, officially referred to as EVERSANA™ COMPLETE COMMERCIALIZATION, gives manufacturers full access to launch strategy, execution and long-term outsourced services (including distribution, field support and patient hub services) through a contracted, multi-year model.

EVERSANA™ COMPLETE COMMERCIALIZATION is helping pharma companies achieve flexible, agile product launches that meet client and patient needs.

Download Greg Skalicky latest’s article to learn how our complete end-to-end commercialization model enables manufacturers to bring their drug to market at a fraction of the cost of “going it alone” or partnering with another pharmaceutical company.

Author Team

EVERSANA employs a team of over 2500 professionals across 27 locations around the world. From industry-leading patient service and adherence support to global pricing and revenue management, our team informs the strategies that matter…